Sydney Lab Unlocks Cancer's Toughest Secrets with Single-Cell Precision

The University of Sydney has just unveiled Australia's first dedicated ACRF Single Cell Cancer Proteomics Laboratory, a massive leap forward in understanding why some cancers stubbornly resist treatment. This cutting-edge facility, housed within the Sydney Mass Spectrometry at the Charles Perkins Centre, will let researchers dive deep into individual cancer and immune cells with unprecedented precision, targeting a significant hurdle in cancer therapy. Up until now, scientists usually studied thousands of cells at once, which meant important differences between individual cells were often missed. This new $4.2 million lab, backed by the Australian Cancer Research Foundation (ACRF) and Cancer Institute NSW, aims to change that by focusing on 'persister cells' – the sly survivors of chemotherapy that often lead to a cancer's return and spread. Led by Associate Professor Mark Larance, the team will use powerful tools like the Orbitrap Astral Zoom Mass Spectrometer to map proteins within single cells, uncovering vulnerabilities for new, targeted drugs. The immediate goal is to apply this single-cell proteomics approach to tough cancers like melanoma, glioblastoma, and persistent breast and prostate cancers. The findings from this national resource could pave the way for truly personalized medicine, giving doctors the ability to select treatments that hit specific cancer cells where they are weakest. This isn't just about Australia; breakthroughs here could ripple globally, transforming how we fight cancer worldwide.